{
     "PMID": "26922073",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20180112",
     "LR": "20180129",
     "IS": "1573-7365 (Electronic) 0885-7490 (Linking)",
     "VI": "31",
     "IP": "4",
     "DP": "2016 Aug",
     "TI": "Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase.",
     "PG": "793-802",
     "LID": "10.1007/s11011-016-9812-3 [doi]",
     "AB": "The objective of this study was to investigate the effect of meloxicam-loaded nanocapsules (M-NC) on the treatment of the memory impairment induced by amyloid beta-peptide (abeta) in mice. The involvement of Na(+), K(+)-ATPase and cyclooxygenase-2 (COX-2) activities in the hippocampus and cerebral cortex was also evaluated. Mice received abeta (3 nmol/ 3 mul/ per site, intracerebroventricular) or vehicle (3 mul/ per site, i.c.v.). The next day, the animals were treated with blank nanocapsules (17 mL/kg) or M-NC (5 mg/kg) or free meloxicam (M-F) (5 mg/kg). Treatments were performed every other day, until the twelfth day. Animals were submitted to the behavioral tasks (open-field, object recognition, Y-maze and step-down inhibitory avoidance tasks) from the twelfth day. Na(+), K(+)-ATPase and COX-2 activities were performed in hippocampus and cerebral cortex. abeta caused a memory deficit, an inhibition of the hippocampal Na(+), K(+)-ATPase activity and an increase in the hippocampal COX-2 activity. M-NC were effective against all behavioral and biochemical alterations, while M-F restored only the COX-2 activity. In conclusion, M-NC were able to reverse the memory impairment induced by abeta, and Na(+), K(+)-ATPase is involved in the effect of M-NC.",
     "FAU": [
          "Ianiski, Francine R",
          "Alves, Catiane B",
          "Ferreira, Carla F",
          "Rech, Virginia C",
          "Savegnago, Lucielli",
          "Wilhelm, Ethel A",
          "Luchese, Cristiane"
     ],
     "AU": [
          "Ianiski FR",
          "Alves CB",
          "Ferreira CF",
          "Rech VC",
          "Savegnago L",
          "Wilhelm EA",
          "Luchese C"
     ],
     "AD": "Programa de Pos-Graduacao em Nanociencias, Centro de Ciencias Tecnologicas, Centro Universitario Franciscano, Santa Maria, CEP 97010-032, RS, Brazil. Programa de Pos-Graduacao em Nanociencias, Centro de Ciencias Tecnologicas, Centro Universitario Franciscano, Santa Maria, CEP 97010-032, RS, Brazil. Programa de Pos-Graduacao em Nanociencias, Centro de Ciencias Tecnologicas, Centro Universitario Franciscano, Santa Maria, CEP 97010-032, RS, Brazil. Programa de Pos-Graduacao em Nanociencias, Centro de Ciencias Tecnologicas, Centro Universitario Franciscano, Santa Maria, CEP 97010-032, RS, Brazil. Grupo de pesquisa em Neurobiotecnologia - GPN, Centro de Desenvolvimento Tecnologico, Unidade Biotecnologia, Universidade Federal de Pelotas, Pelotas, CEP: 96010-900, RS, Brazil. Grupo de pesquisa em Neurobiotecnologia - GPN, Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Capao do Leao, Pelotas, CEP 96010-900, RS, Brazil. ethelwilhelm@yahoo.com.br. Grupo de pesquisa em Neurobiotecnologia - GPN, Centro de Ciencias Quimicas, Farmaceuticas e de Alimentos, Universidade Federal de Pelotas, Campus Capao do Leao, Pelotas, CEP 96010-900, RS, Brazil. cristiane_luchese@yahoo.com.br.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20160227",
     "PL": "United States",
     "TA": "Metab Brain Dis",
     "JT": "Metabolic brain disease",
     "JID": "8610370",
     "RN": [
          "0 (Nanocapsules)",
          "0 (Thiazines)",
          "0 (Thiazoles)",
          "EC 1.14.99.1 (Cyclooxygenase 2)",
          "EC 3.6.3.9 (Sodium-Potassium-Exchanging ATPase)",
          "VG2QF83CGL (meloxicam)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/*drug therapy/metabolism",
          "Animals",
          "Behavior, Animal/drug effects",
          "Cerebral Cortex/drug effects/metabolism",
          "Cyclooxygenase 2/metabolism",
          "Disease Models, Animal",
          "Hippocampus/drug effects/metabolism",
          "Memory/drug effects",
          "Memory Disorders/*drug therapy/metabolism",
          "Mice",
          "Nanocapsules/*administration & dosage",
          "Sodium-Potassium-Exchanging ATPase/*metabolism",
          "Thiazines/administration & dosage/*therapeutic use",
          "Thiazoles/administration & dosage/*therapeutic use"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*Amyloid-beta",
          "*Cyclooxygenase",
          "*Drug-delivery",
          "*Meloxicam",
          "*Nanoparticles"
     ],
     "EDAT": "2016/02/29 06:00",
     "MHDA": "2018/01/13 06:00",
     "CRDT": [
          "2016/02/29 06:00"
     ],
     "PHST": [
          "2015/08/13 00:00 [received]",
          "2016/02/17 00:00 [accepted]",
          "2016/02/29 06:00 [entrez]",
          "2016/02/29 06:00 [pubmed]",
          "2018/01/13 06:00 [medline]"
     ],
     "AID": [
          "10.1007/s11011-016-9812-3 [doi]",
          "10.1007/s11011-016-9812-3 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Metab Brain Dis. 2016 Aug;31(4):793-802. doi: 10.1007/s11011-016-9812-3. Epub 2016 Feb 27.",
     "term": "hippocampus"
}